Skip to main content

Main menu

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
    • Special Issues
  • Journal Metrics
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Anticancer Research
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Anticancer Research

Advanced Search

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
    • Special Issues
  • Journal Metrics
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Visit us on Facebook
  • Follow us on Linkedin
Research ArticleClinical Studies

Long-term Survivors After Liver Resection for Ovarian Cancer Liver Metastases

NICOLAE BACALBAȘA, IRINA BALESCU, SIMONA DIMA and IRINEL POPESCU
Anticancer Research December 2015, 35 (12) 6919-6923;
NICOLAE BACALBAȘA
1Department of Obstetrics and Gynecology, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: nicolae_bacalbasa{at}yahoo.ro
IRINA BALESCU
2Department of General Surgery, Ponderas Hospital, Bucharest, Romania
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
SIMONA DIMA
3Dan Setlacec Center of Gastrointestinal Disease and Liver Transplantation, Fundeni Clinical Institute, Bucharest, Romania
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
IRINEL POPESCU
1Department of Obstetrics and Gynecology, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania
3Dan Setlacec Center of Gastrointestinal Disease and Liver Transplantation, Fundeni Clinical Institute, Bucharest, Romania
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

Ovarian cancer is one of the most aggressive gynecological malignancies and most patients are diagnosed at an advanced stage of disease. In these cases, the best therapeutic approach in order to provide good control remains an aggressive surgical approach leading to complete R0 resection. The experience provided by performing liver resection for colorectal hepatic metastases in association with the observation that residual disease remains the most important prognostic factor in ovarian cancer encouraged surgeons worldwide to include hepatic resection as part of the therapeutic armamentarium in ovarian cancer liver metastases. Patients and Methods: Data of patients submitted to liver resection for ovarian cancer liver metastases were retrospectively reviewed. The main inclusion criterion for the current study was a reported survival greater than 5 years after hepatic resection. Results: Eight patients were eligible for study inclusion: four cases were submitted to liver resection during primary cytoreduction, two cases were submitted to liver resection as part of secondary cytoreduction while the other two cases underwent hepatic resection at the moment of tertiary cytoreduction. In all cases R0 resection was achieved. Postoperatively one patient developed an abdominal abscess requiring for percutaneous drainage and one patient developed a hemoperitoneum necessitating re-operation. The mean overall survival was 123 months for patients submitted to liver resection as part of primary cytoreduction; patients submitted to liver resection as part of secondary cytoreduction experienced an overall survival of 66 and 73 months, respectively, while patients submitted to liver resection as part of tertiary cytoreductive surgery are alive at 5-year follow-up. Conclusion: In selected cases liver resection for ovarian cancer liver metastases can be associated with a significant increase of the overall survival.

  • Ovarian cancer liver metastases
  • long-term survival
  • hepatic resection

Ovarian cancer remains one of the most aggressive gynecological malignancies being responsible for the highest number of gynecological cancer-related deaths (1). This aspect is especially related to the fact that most women are diagnosed in an advanced stage of the disease when distant metastases are already present. It has been widely demonstrated that ovarian cancer has a high capacity to induce distant metastases via the peritoneal, hematogenous and lymphatic route (2). Initially it has been considered that the presence of upper abdomen involvement is a sign of a tumor with a more aggressive biology and with a poorer outcome. However the improvement of surgical technique and success reported after resection of liver metastases from colorectal or neuro-endocrine primaries enabled surgeons worldwide to introduce liver resection as part of therapeutic armamentarium for advanced stage or relapsed ovarian cancer with hepatic involvement (3, 4). Although according to International Federation of Obstetrics and Gynecology (FIGO) classification there are two sub-types of liver metastases from ovarian cancer-peritoneal seeding and hematogenous seeding, studies so far, demonstrated that in both cases a significant advantage in terms of survival is expected if the principles of complete cytoreduction are applied (5-7).

Patients and Methods

After obtaining the approval of the Ethics Committee (no 153/2015) data of patients submitted to liver resection as part of debulking surgery for advanced stage or relapsed ovarian cancer at the ‘Dan Setlacec’ Center of Gastrointestinal Disease and Liver Transplantation, Fundeni Clinical Institute, Bucharest were retrospectively reviewed. Patients eligible for the study were considered those who reported a greater than 60 months survival after liver resection for advanced stage or relapsed ovarian cancer. The goal of debulking surgery was an R0 resection, defined as no residual disease; residual disease between 0-1 cm was considered as R1 resection while cases in which residual disease larger than 1 cm was achieved, were classified as R2 resections. Liver metastases were considered as having hematogenous origin if the lesion was entirely surrounded by normal parenchyma while peritoneal seeding was incriminated if the liver lesion originated from the liver capsula and associated a parenchymal invasion of at least 2 cm. Minor hepatectomies were defined as liver resection of at least 2 segments according to Couinaud's classification while resections of more than 2 segments were classified as major hepatectomies. The postoperative morbidity was classified according to Clavien-Dindo scale (8).

Results

Eight patients were considered eligible for the study. Four of the eight patients were submitted to liver resection as part of primary cytoreduction while the other four patients were submitted to liver resection as part of cytoreduction for relapsed ovarian cancer.

Liver resection as part of primary cytoreduction. The mean age at diagnosis of advanced-stage ovarian cancer was 52 years (range=42-60 years) while the initial FIGO stage was IIIC in one case and IV in the other three cases. In all cases preoperative imaging examination revealed the presence of a single liver lesion with diameter ranging between 2 and 4 cm. All cases were submitted to surgery with radical intent, an R0 resection being achieved in all cases. The main associated visceral resections consisted of total hysterectomy with bilateral adnexectomy in three cases, omentectomy, pelvic and parietal peritonectomy in four cases, pelvic and para-aortic lymph node dissection in one case and rectosigmoidectomy in one case; partial resection of the right diaphragm was also performed in one case. Case 4 had been initially submitted to total hysterectomy with unilateral adnexectomy twelve years previously for uterine leiomyoma and serous ovarian cyst. Twelve years later she presented for abdominal pain and weight loss and was diagnosed with an ovarian tumor on the remnant adnexa and bulky omental and peritoneal lesions. The patient was submitted to surgery in another surgical unit where an adnexectomy was performed; the patient was submitted to six cures of taxanes and platinum based chemotherapy. One month after ending the chemotherapeutic protocol she was re-submitted to surgery and total omentectomy, pelvic, parietal peritonectomy and atypical hepatectomy were performed, an R0 resection being achieved. All the other three cases were submitted to surgery as first intention therapy.

The main characteristics of the patients submitted to liver resection as part of primary cytoreduction are shown in Table I. The histopathological studies confirmed the presence of ovarian cancer liver metastases in all cases. The main pathological characteristics are summarized in Table II.

The postoperative course was uneventful for cases 2, 3 and 4 while case 1 developed a Clavien–Dindo grade 2 complication, a mild pleural effusion that was successfully managed conservatively. The median hospital in stay was 11 days (ranging 9-16 days).

When it comes to long-term outcomes, the median overall survival was 123 months, all patients being dead of disease at the end of the study.

Liver resection as part of cytoreductive surgery for relapsed ovarian cancer. The other four cases were submitted to liver resection for ovarian cancer liver metastases in the setting of recurrent disease. Two of the four patients were submitted to liver resection as part of secondary cytoreduction. The patients had been diagnosed with FIGO stage IIIC and IC respectively at the ages of 48 and 49 years respectively. At the moment of initial diagnosis the patient with FIGO stage IIC disease was submitted to total hysterectomy, bilateral adnexectomy and omentectomy followed by six cycles of adjuvant chemotherapy and experienced a disease-free survival of 28 months. At the moment of first relapse she was directly submitted to surgery and a transverse colectomy, splenectomy, atypical hepatectomy, total peritonectomy and appendectomy were performed. Histopathological studies revealed the presence of a medium differentiated serous ovarian adenocarcinoma. The specimen of atypical hepatectomy showed the presence of a 4-cm unique liver metastasis with hematogenous origin while the specimen of splenectomy revealed the presence of capsular lesions invading the splenic parenchyma. The patient developed an intra-abdominal abscess which was successfully treated in a conservative manner (Clavien-Dindo grade 2 complication) and was discharged in the 12th postoperative day. Postoperatively she was submitted to six other cycles of taxanes and platinum-based chemotherapy and experienced a disease-free survival of 48 months; at that moment she was diagnosed with disseminated intra-abdominal lesions and was resubmitted to surgery with palliative intent. Finally she died of disease 66 months after secondary cytoreduction.

The second patient submitted to liver resection as part of secondary cytoreduction had been initially diagnosed with FIGO stage IC disease at the age of 49 years. At that moment a total hysterectomy and bilateral adnexectomy were performed followed by three cycles of adjuvant taxanes and platinum based chemotherapy. Four years later she was diagnosed with pelvic recurrence and hepatic isolated recurrence and was submitted to surgery with curative intent: the pelvic recurrence was resected en bloc with total cystectomy and rectosigmoidian resection while the liver lesion was resected by performing an atypical hepatectomy; an R0 resection was achieved. The histopathological studies revealed the presence of a 2-cm well-differentiated serous ovarian metastases with peritoneal origin. The postoperative course was uneventful the patient being discharged in the 8th postoperative day. At 10 year follow-up after secondary cytoreduction the patient is alive with no signs of recurrent disease.

View this table:
  • View inline
  • View popup
  • Download powerpoint
Table I.

Characteristics of patients submitted to liver resection as part of primary cytoreduction.

In both cases minor liver resections were performed. The patient died of disease 73 months after tertiary cytoreduction.

The other two patients were submitted to liver resection as part of tertiary cytoreduction for relapsed ovarian cancer. The patients had been diagnosed with FIGO stage IC and IIC disease respectively and submitted to tertiary cytoreduction at 74 and 82 months respectively. The first patient was diagnosed with an isolated liver metastasis at the moment of second relapse and was submitted to a major hepatectomy. The histopathological study confirmed the presence of a poorly differentiated serous ovarian adenocarcinoma liver metastasis with hematogenous origin. It was a unique liver metastasis measuring 4 cm with microscopically-negative resection margins. During the early postoperative course the patient developed a postoperative hemoperitoneum necessitating re-operation. At 5-year follow-up the patient reports no recurrent disease.

The last patient was initially diagnosed with FIGO stage IIC ovarian cancer and was submitted to tertiary cytoreduction at 82 months from the moment of diagnosis. At the moment of tertiary cytoreduction an R0 resection was achieved; the recurrences were resected en bloc with total cystectomy, splenectomy, parcelar gastrectomy and atypical hepatectomy. The histopathological studies of the specimen of hepatectomy revealed the presence of a 3 cm lesion with peritoneal origin, with negative resection margin. The postoperative course was uneventful, the patient being discharged in the 7th postoperative day. At 5-year follow-up she is alive with recurrent disseminated lesions and she was submitted to palliative chemotherapy.

Discussion

Hepatic resection has been proven a safe and effective method in treating colorectal liver metastases leading in time to a significant benefit in terms of survival when compared to cases treated by chemotherapeutic regimens only (3, 4). In the meantime, when it comes to ovarian cancer, it has been widely demonstrated that the only parameter which significantly and constantly influences the long-term survival is the completeness of resection, this fact being the only one which can be influenced by the surgeon. Progresses reported in the upper abdomen surgical technique and postoperative management leaded in time to an increase of the rate of cytoreduction to no residual disease even in cases with upper abdominal burden (9-11).

In the study conducted by Eisenhauer regarding the efficacy of the addition of upper abdominal surgery in order to achieve complete cytoreduction the authors included 262 patients with stages IIIC and IV ovarian cancers. The patients were submitted to surgery from 1998 to 2003 at the Memorial Sloan Kettering Cancer Center and were divided in three groups: the first group included patients submitted to cytoreductive surgery including upper abdomen procedures, the second group included cases with no upper tumoral burden in which complete cytoreduction was achieved after performing pelvic resections and the third group included patients with upper tumoral burden sub-optimally cytoreduced. Patients included in the first two groups reported similar frequencies of achieving a complete clinical response, similar disease free survival intervals and similar overall survival rates. Oppositely to the first two groups, patients included in the third group reported significantly shorter disease-free survival and overall survival rates (p<0.001) although a faster recuperation and initiation of adjuvant chemotherapy was achieved. Liver resection was safely performed in 16% of cases in group 1, the rate of postoperative complications being similar between the three groups (p=0.54). The study came to demonstrate that the principles of debulking surgery can be safely applied in patients presenting upper abdominal tumor burden; in the meantime the authors demonstrated that the presence of upper abdomen involvement is not the distinctive sign of a poor tumor biology and significant improve of survival is expected if an R0 resection is performed (12).

View this table:
  • View inline
  • View popup
  • Download powerpoint
Table II.

Histopathological characteristics of resection specimens.

Once it had been widely demonstrated that upper abdominal resections can be safely applied, with acceptable rates of postoperative complications and significantly improved survival, attention was focused on the role of liver resection as part of cytoreductive surgery for advanced-stage and relapsed ovarian cancer.

In the study conducted by Kolev et al. 76 patients submitted to liver resection for advanced-stage or relapsed ovarian cancer with hepatic involvement were included. Out of the 76 cases, 27 cases were submitted to liver resection as part of secondary cytoreduction. In 15 cases multiple hepatic lesions were found while in the other 12 cases isolated liver metastases were revealed. The main types of liver resection included segmentectomy (in 11 cases) and wedge resections (in 9 cases) followed by major resections such as multi-segmentectomy (in 3 cases) and lobectomy (in 4 cases). The postoperative morbidity rate was 11%, three cases experiencing high-grade complications. The median overall survival after liver resection was 12 months (range=2-190 months) and was significantly influenced by the interval from the first surgery (p=0,044) and the diameter of the residual disease (p=0.014) while the number of liver resection did not significantly impacted on survival (p=0.97) (13).

In order to demonstrate that a significant increase of survival can be achieved especially in patients with isolated liver lesions, Salih Pekmezci et al. included in their study eight patients with isolated hepatic metastases from ovarian cancer. The mean disease-free survival from the time of initial surgery to surgery for metastatic hepatic lesion was 5,38 years. The main surgical procedures performed were segmentectomy in three cases followed by left lateral sectorectomy and atypical hepatectomy, each in two cases and right hepatectomy in one case. The reported survival ranged between 7 months (the patient being dead due to sudden cardiac arrest) and 5 years (all four cases which were alive at 5-yearfollow-up had no evidence of recurrent disease). The authors reported a single patient who died three years after liver resection due to progression of the disease leading to multiple distant metastases. The authors concluded that a prolonged survival should be expected especially in cases with an initial long disease-free interval (between primary and secondary cytoreduction), this fact being an indicator of a good biological tumor behavior. In their opinion, another prognostic factor for a prolonged survival is the number of liver lesions, the presence of isolated ovarian cancer liver metastases being an important selection criterion (14). Similarly to Pekmezci's study the long survivors identified in our study were in almost all cases patients with long disease-free intervals and isolated liver lesions.

Similar results were also reported by Sam Yoon's study conducted on 24 patients with recurrent ovarian (21 cases) or fallopian tube (3 cases) carcinoma with liver involvement. The majority of patients experienced a slow tumoral progression from the moment of initial diagnosis (the median interval between primary diagnosis and hepatic resection being 68.5 months). At the time of diagnosis of liver metastases 17 cases presented a single liver lesion, 6 cases were diagnosed with two liver lesions and the last patient had five liver lesions. In six cases a liver-confined relapse was found, in 7 cases both liver and contiguous sites were revealed while in the other 11 patients both liver and non-contiguous site metastases were diagnosed. The main surgical procedures included segmentectomies (in 17 cases) followed by wedge resections (in 3 cases), lobectomies (in 2 cases) and trisegmentectomies (in the other 2 cases). The overall morbidity rate was 21% while the mortality rate was null; however a single patient developed a liver-related surgery complication – a bilioma. The authors reported a median overall survival of 62 months, three patients being alive at 5-year follow-up: two cases were reported to be alive with disease while the third patient had no evidence of disease 9 years after resection. The authors concluded that the ideal candidates for ovarian cancer liver metastases resection in which a maximal benefit in terms of survival is expected are those with favorable tumor biology (slow growing tumors, limited to liver recurrence or limited extra-hepatic disease, long disease free intervals) and with a good biological status. In the meantime the extent of liver resection (major versus minor resection) and the dimension of the largest hepatic metastasis did not influence the outcome (15).

Conclusion

Hepatic resection for ovarian cancer liver metastases is a safe and effective surgical procedure successfully associated as part of debulking surgery for advanced and relapsed ovarian cancer. Long-term survivors should be expected among patients with increased disease-free intervals and isolated recurrences. Although major hepatic resections might be needed, the magnitude of liver resection does not seem to influence the outcomes. When it comes to the pattern of spread a significant benefit in terms of survival was achieved for cases with both peritoneal and hematogenous lesions.

Footnotes

  • This article is freely accessible online.

  • Received August 20, 2015.
  • Revision received September 25, 2015.
  • Accepted September 29, 2015.
  • Copyright© 2015 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved

References

  1. ↵
    1. Greenlee RT,
    2. Hill-Harmon MB,
    3. Murray T,
    4. Thun M
    : Cancer statistics, 2001. CA Cancer J Clin 51: 15-36, 2001.
    OpenUrlCrossRefPubMed
  2. ↵
    1. Nakayama K,
    2. Nakayama N,
    3. Katagiri H,
    4. Miyazaki K
    : Mechanisms of ovarian cancer metastasis: biochemical pathways. Int J Mol Sci 13: 11705-11717, 2012.
    OpenUrlCrossRefPubMed
  3. ↵
    1. Kim JC,
    2. Kim CN,
    3. Yu CS,
    4. Lee HI,
    5. Kim SW,
    6. Lee JH,
    7. Kim WK,
    8. Kang GH,
    9. Lee MK
    . Treatment of Hepatic Metastasis of Colorectal Cancer: A Retrospective Analysis of the Outcome in 99 Patients. J Korean Cancer Assoc 30: 1175–1183, 1998.
    OpenUrl
  4. ↵
    1. Kuvshinoff B,
    2. Fong Y
    : Surgical therapy of liver metastases. Semin Oncol 34: 177-185, 2007.
    OpenUrlCrossRefPubMed
  5. ↵
    1. Bacalbasa N,
    2. Dima S,
    3. Brasoveanu V,
    4. David L,
    5. Balescu I,
    6. Purnichescu-Purtan R,
    7. Popescu I
    : Liver resection for ovarian cancer liver metastases as part of cytoreductive surgery is safe and may bring survival benefit. World J Surg Oncol 13: 235, 2015.
    OpenUrlPubMed
    1. Bosquet JG,
    2. Merideth MA,
    3. Podratz KC,
    4. Nagorney DM
    : Hepatic resection for metachronous metastases from ovarian carcinoma. HPB (Oxford) 8: 93-96, 2006.
    OpenUrlPubMed
  6. ↵
    1. Niu GC,
    2. Shen CM,
    3. Cui W,
    4. Li Q
    : Hepatic Resection is Safe for Metachronous Hepatic Metastases from Ovarian Cancer. Cancer Biol Med 9: 182-187, 2012.
    OpenUrlPubMed
  7. ↵
    1. Dindo D,
    2. Demartines N,
    3. Clavien PA
    : Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg 240: 205-213, 2004.
    OpenUrlCrossRefPubMed
  8. ↵
    1. Scarabelli C,
    2. Gallo A,
    3. Carbone A
    : Secondary cytoreductive surgery for patients with recurrent epithelial ovarian carcinoma. Gynecol Oncol 83: 504-512, 2001.
    OpenUrlCrossRefPubMed
    1. Chi DS,
    2. Fong Y,
    3. Venkatraman ES,
    4. Barakat RR
    : Hepatic resection for metastatic gynecologic carcinomas. Gynecol Oncol 66: 45-51, 1997.
    OpenUrlCrossRefPubMed
  9. ↵
    1. Zivanovic O,
    2. Eisenhauer EL,
    3. Zhou Q,
    4. Iasonos A,
    5. Sabbatini P,
    6. Sonoda Y,
    7. Abu-Rustum NR,
    8. Barakat RR,
    9. Chi DS
    : The impact of bulky upper abdominal disease cephalad to the greater omentum on surgical outcome for stage IIIC epithelial ovarian, fallopian tube and primary peritoneal cancer. Gynecol Oncol 108: 287-292, 2008.
    OpenUrlCrossRefPubMed
  10. ↵
    1. Eisenhauer EL,
    2. Abu-Rustum NR,
    3. Sonoda Y,
    4. Levine DA,
    5. Poynor EA,
    6. Aghajanian C,
    7. Jarnagin WR,
    8. DeMatteo RP,
    9. D'Angelica MI,
    10. Barakat RR,
    11. Chi DS
    : The addition of extensive upper abdominal surgery to achieve optimal cytoreduction improves survival in patients with stages IIIC-IV epithelial ovarian cancer. Gynecol Oncol 103: 1083-1090, 2006.
    OpenUrlCrossRefPubMed
  11. ↵
    1. Kolev V,
    2. Pereira EB,
    3. Schwartz M,
    4. Sarpel U,
    5. Roayaie S,
    6. Labow D,
    7. Momeni M,
    8. Chuang L,
    9. Dottino P,
    10. Rahaman J,
    11. Zakashansky K
    : The role of liver resection at the time of secondary cytoreduction in patients with recurrent ovarian cancer. Int J Gynecol Cancer 24: 70-74, 2014.
    OpenUrlPubMed
  12. ↵
    1. Pekmezci S,
    2. Saribeyoglu K,
    3. Aytac E,
    4. Arvas M,
    5. Demirkiran F,
    6. Ozguroglu M
    : Surgery for isolated liver metastasis of ovarian cancer. Asian J Surg 33: 83-88, 2010.
    OpenUrlPubMed
  13. ↵
    1. Yoon SS,
    2. Jarnagin WR,
    3. Fong Y,
    4. DeMatteo RP,
    5. Barakat RR,
    6. Blumgart LH,
    7. Chi DS
    : Resection of recurrent ovarian or fallopian tube carcinoma involving the liver. Gynecol Oncol 91: 383-388, 2003.
    OpenUrlCrossRefPubMed
PreviousNext
Back to top

In this issue

Anticancer Research
Vol. 35, Issue 12
December 2015
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Back Matter (PDF)
  • Ed Board (PDF)
  • Front Matter (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Anticancer Research.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Long-term Survivors After Liver Resection for Ovarian Cancer Liver Metastases
(Your Name) has sent you a message from Anticancer Research
(Your Name) thought you would like to see the Anticancer Research web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
1 + 0 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Citation Tools
Long-term Survivors After Liver Resection for Ovarian Cancer Liver Metastases
NICOLAE BACALBAȘA, IRINA BALESCU, SIMONA DIMA, IRINEL POPESCU
Anticancer Research Dec 2015, 35 (12) 6919-6923;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Reprints and Permissions
Share
Long-term Survivors After Liver Resection for Ovarian Cancer Liver Metastases
NICOLAE BACALBAȘA, IRINA BALESCU, SIMONA DIMA, IRINEL POPESCU
Anticancer Research Dec 2015, 35 (12) 6919-6923;
Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Patients and Methods
    • Results
    • Discussion
    • Conclusion
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

Cited By...

  • Normal Size Ovary Carcinoma Syndrome with Inguinal Ovarian Cancer Lymph Node Metastases - A Case Report and Literature Review
  • Association of Diaphragmatic Surgery as Part of Cytoreductive Effort in Advanced Stage Ovarian Cancer
  • Debulking Surgery for Clear Cell Carcinoma of the Ovary - A Case Report and Literature Review
  • Rectosigmoidian Involvement in Advanced-stage Ovarian Cancer - Intraoperative Decisions
  • Multiple Visceral Resections for Synchronous Left and Transverse Colon Adenocarcinoma with Gastrocolic-cutaneous Fistula - Case Report and Literature Review
  • Partial Cystectomy for Atypical Isolated Recurrence of Ovarian Adenocarcinoma - A Case Report and Literature Review
  • Solitary Splenic Metastasis After Surgically-treated Cervical Cancer - A Case Report and Literature Review
  • What Characterizes Long-term Survivors of Recurrent Ovarian Cancer? Case Report and Review of the Literature
  • Local Therapies Can Improve Intracerebral Control in Patients with Cerebral Metastasis from Gynecological Cancers
  • Google Scholar

More in this TOC Section

  • Efficacy of Platinum-based Chemotherapy for Platinum-sensitive Recurrent Ovarian Cancer During PARP Inhibitor Treatment: A Multicenter Retrospective Study
  • Uniformity Between Serological Biomarker Test, Esophago-gastro-duodenoscopy and Biopsy Histology in Triage of Upper Abdominal Symptoms in Gastroscopy Referral Patients
  • Renal Function With Enfortumab Vedotin in Metastatic Urothelial Carcinoma: A Multicenter Retrospective Study in Japan
Show more Clinical Studies

Keywords

  • Ovarian cancer liver metastases
  • long-term survival
  • hepatic resection
Anticancer Research

© 2025 Anticancer Research

Powered by HighWire